The importance of coexpression of myeloid antigens in childhood acute lymphoblastic leukemia (ALL) has long been debated; results are conflicting. We studied children with ALL treated at Italian Association for Pediatric Hematology-Oncology (AIEOP) institutions over 6 years with Berlin-Frankfurt-Muenster (BFM)-based protocols and have analyzed the incidence of coexpression of six MyAg (CD11b, CD13, CD14, CD15, CD33, CD65w) to determine its prognostic impact. Criteria for MyAg coexpression (MyAg(+)ALL) included positivity to one or more MyAg on at least 20% of blasts and confirmation of coexpression at double-fluorescence analysis. A total of 291 of 908 cases were MyAg+ALL (32%). Incidence was similar in B-ALL and T-ALL; among common, pre-B, and pre-pre-B-ALL. CD13 and CD33 were most common. Patients with MyAg(+)ALL had presenting features similar to MyAg(-)ALL. They entered standard or intermediate risk protocols more frequently and had better prednisone response, but similar complete remission rates. Six-year event-free survival (EFS) was 69.0% in 291 MyAg(+)ALL cases and 65.3% in 617 MyAg(-)ALL cases, without significant difference. Cases expressing two or more MyAg presented similar clinical features and treatment response. MyAg(+)ALL had worse EFS only in infants (0% v 47%) (P =.01). Therefore, in this series of homogeneously diagnosed and treated ALL, coexpression of MyAg was not associated with prognostic significance, without relevance for clinical purposes or for patient stratification, except for infants.
|Autori interni:||CONSOLINI, RITA|
|Autori:||PUTTI MC.; RONDELLI R.; COCITO MG.; ARICO' M.; CONSOLINI R|
|Titolo:||EXPRESSION OF MYELOID MARKERS LACKS PROGNOSTIC IMPACT IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA: ITALIAN EXPERIENCE IN AIEOP-ALL 88-91 STUDIES|
|Anno del prodotto:||1998|
|Appare nelle tipologie:||1.1 Articolo in rivista|